Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature - 14/11/13
Abstract |
Background |
Publications reporting photodynamic therapy (PDT) in mycosis fungoides (MF) are rare, involve small samples, and are difficult to compare because of a lack of technical standardization.
Objective |
We sought to assess PDT effectiveness and tolerability in early-stage MF using a strict reproducible procedure.
Methods |
This was a prospective study conducted in Nantes University Hospital, France, including patients older than 18 years with histologically proven MF (stage IA or IB). Methyl-aminolevulinic acid-PDT sessions were repeated monthly for 6 months. Clinical and histologic responses were assessed 1 month after the last session. Patient satisfaction was assessed by telephone survey.
Results |
Twelve patients (with 29 lesions) were treated with PDT. An objective response in target lesions was obtained in 75% of patients. Response rates were similar between plaques and patches but higher in sun-protected compared with sun-exposed areas (trend without reaching significance). During PDT, new lesions appeared in 5 of 12 patients in untreated areas. Most patients were highly satisfied and preferred PDT to the topical chemotherapy previously used.
Limitations |
PDT procedure criteria selection was partially arbitrary.
Conclusions |
In early-stage MF, PDT is effective and appreciated (especially when compared with conventional topical chemotherapy). Unilesional and paucilesional forms and lesions in sun-protected areas are to be preferred.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous T-cell lymphoma, methyl-aminolevulinic acid, mycosis fungoides, photodynamic therapy, prospective study, satisfaction survey
Abbreviations used : CR, EORTC, ISCL, MAL, MF, PDT, PR
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 69 - N° 6
P. 890-897 - décembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?